Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an options trading signal again: unusual options activity screeners and strategies. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Gilead Sciences Inc (GILD)
Gilead Sciences Inc (GILD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 96,158,440
  • Shares Outstanding, K 1,247,353
  • Annual Sales, $ 27,281 M
  • Annual Income, $ 4,592 M
  • 60-Month Beta 0.38
  • Price/Sales 3.55
  • Price/Cash Flow 8.65
  • Price/Book 4.63
Trade GILD with:

Options Overview Details

View History
  • Implied Volatility 22.81% ( -0.07%)
  • Historical Volatility 16.10%
  • IV Percentile 23%
  • IV Rank 41.45%
  • IV High 30.84% on 10/12/22
  • IV Low 17.12% on 03/06/23
  • Put/Call Vol Ratio 0.42
  • Today's Volume 7,765
  • Volume Avg (30-Day) 9,323
  • Put/Call OI Ratio 0.88
  • Today's Open Interest 244,473
  • Open Int (30-Day) 254,245

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/23
See More
  • Average Estimate 1.66
  • Number of Estimates 10
  • High Estimate 1.81
  • Low Estimate 1.54
  • Prior Year 1.58
  • Growth Rate Est. (year over year) +5.06%

Price Performance

See More
Period Period Low Period High Performance
1-Month
76.26 +1.09%
on 05/25/23
83.86 -8.07%
on 04/27/23
-6.65 (-7.94%)
since 04/26/23
3-Month
76.26 +1.09%
on 05/25/23
87.37 -11.77%
on 04/24/23
-3.57 (-4.43%)
since 02/24/23
52-Week
57.17 +34.86%
on 06/14/22
89.74 -14.10%
on 12/13/22
+12.62 (+19.57%)
since 05/26/22

Most Recent Stories

More News
Promising Developments Announced Ahead of 2023 ASCO Annual Meeting's Oral Presentations

/PRNewswire/ -- USA News Group - The world's biggest cancer conference is set to roll again at American Society of Clinical Oncology (ASCO) 2023, with...

ONC.TO : 2.36 (-19.45%)
GILD : 77.09 (-0.72%)
IMGN : 14.00 (+1.30%)
DAWN : 12.47 (+3.40%)
LEGN : 63.13 (-0.24%)
ONCY : 1.7500 (-18.98%)
Promising Developments Announced Ahead of 2023 ASCO Annual Meeting’s Oral Presentations

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GILD),(NASDAQ:IMGN),(NASDAQ:DAWN),(NASDAQ:LEGN) EQNX::TICKER_END

ONCY : 1.7500 (-18.98%)
ONC.TO : 2.36 (-19.45%)
GILD : 77.09 (-0.72%)
IMGN : 14.00 (+1.30%)
DAWN : 12.47 (+3.40%)
LEGN : 63.13 (-0.24%)
Promising New Cancer Treatment Data to Be Presented at 2023 ASCO Annual Meeting

VANCOUVER - USA News Group - The world’s biggest cancer conference is set to roll again at American Society of Clinical Oncology (ASCO) 2023, with in-person attendance back in full swing and already...

ONCY : 1.7500 (-18.98%)
ONC.TO : 2.36 (-19.45%)
GILD : 77.09 (-0.72%)
IMGN : 14.00 (+1.30%)
DAWN : 12.47 (+3.40%)
LEGN : 63.13 (-0.24%)
There are Positive Developments in the Treatment of Metastatic Breast Cancer

A significant medical breakthrough is desperately needed in the fight against metastatic breast cancer. As it stands right now, metastatic breast cancer has no cure and has proven resistant to many cancer...

LLY : 425.79 (-0.36%)
PBYI : 3.19 (-0.31%)
GILD : 77.09 (-0.72%)
IMGN : 14.00 (+1.30%)
BCTX : 5.87 (-2.98%)
BCT.TO : 8.07 (-1.82%)
3 Relatively Safe Stocks to Buy if a Recession Is on the Way

If the economy falters, these stocks should hold up better than most.

ABBV : 137.56 (-0.76%)
GILD : 77.09 (-0.72%)
JNJ : 154.35 (-0.04%)
Vertex Pharmaceuticals Hits Record High on Strong Q1 Earnings

Vertex Pharmaceuticals hits record high on strong earnings, FDA approval for cystic fibrosis medication for infants. Analysts recently boosted price targets.

VRTX : 329.99 (-0.79%)
CRSP : 64.66 (+1.27%)
TRDA : 11.76 (-1.34%)
MRNA : 126.24 (-0.18%)
GILD : 77.09 (-0.72%)
AMGN : 216.93 (-0.24%)
Markets Today: Stocks Slip Ahead of U.S. Debt Ceiling Talks

Morning Markets June E-Mini S&P 500 futures (ESM2 3) this morning are down -0.26%, and June Nasdaq 100 E-Mini futures (NQM2 3) are down -0.21%. U.S. stock index futures this morning are moderately lower...

ESM23 : 4,226.25 (+0.31%)
NQM23 : 14,409.75 (+0.54%)
HD : 292.83 (+2.12%)
HZNP : 99.61 (-0.27%)
RUM : 9.55 (-3.73%)
FWRG : 17.92 (+0.11%)
RH : 246.82 (-3.07%)
DCO : 40.76 (-0.59%)
COF : 102.85 (+2.93%)
BEEM : 12.04 (+2.03%)
GILD : 77.09 (-0.72%)
NVCR : 73.56 (-5.03%)
S&P Futures Tick Lower Ahead of Key U.S. Retail Sales Data, Debt-Ceiling Talks in Focus

June S&P 500 futures (ESM23) are trending down -0.14% this morning as market participants digested soft Chinese economic data while awaiting an update on plans to raise the federal debt limit as well as...

ESM23 : 4,226.25 (+0.31%)
META : 262.04 (+3.70%)
WDC : 39.71 (+4.91%)
PACW : 7.11 (+4.41%)
ZION : 28.66 (+1.20%)
EMBRB.S.DX : 23.790 (+13.18%)
TIT.M.DX : 0.257 (-1.53%)
BEEM : 12.04 (+2.03%)
COF : 102.85 (+2.93%)
DOX : 96.75 (+1.34%)
DCO : 40.76 (-0.59%)
GILD : 77.09 (-0.72%)
Five Impressive Metastatic Cancer Treatment Stocks to Own Today

A significant medical breakthrough is desperately needed in the fight against breast cancer. At the moment, according to the American Cancer Society, more than 3.1 million women in the United States alone...

LLY : 425.79 (-0.36%)
PBYI : 3.19 (-0.31%)
GILD : 77.09 (-0.72%)
IMGN : 14.00 (+1.30%)
BCTX : 5.87 (-2.98%)
BCT.TO : 8.07 (-1.82%)
Gilead Sciences Stock: Bear vs. Bull

The S&P 500 has outperformed Gilead over the past five years.

GILD : 77.09 (-0.72%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

Gilead Sciences is a pioneer in developing drugs for the treatment of human immunodeficiency virus, liver diseases, hematology/oncology diseases and inflammation/respiratory diseases. The company has a strong HIV franchise with key HIV/AIDS therapies like tenofovir alafenamide based products - Genvoya,...

See More

Key Turning Points

3rd Resistance Point 79.75
2nd Resistance Point 79.18
1st Resistance Point 78.14
Last Price 77.09
1st Support Level 76.53
2nd Support Level 75.96
3rd Support Level 74.92

See More

52-Week High 89.74
Fibonacci 61.8% 77.30
Last Price 77.09
Fibonacci 50% 73.45
Fibonacci 38.2% 69.61
52-Week Low 57.17

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar